Contact Hours: 4
This educational activity is credited for 4 contact hours at completion of the activity.
Course Purpose
The purpose of this course is to provide healthcare professionals with an overview of frontotemporal dementia (FTD), and explore its symptoms, types, causes, diagnostics methods, treatment options, potential complications, management strategies, and nursing considerations to improve the quality of life for individuals affected by frontotemporal dementia.
Overview
Dementia arises from a diverse array of diseases and injuries that affect the brain, causing cognitive decline and functional impairment. Frontotemporal Dementia (FTD) represents a distinct form of dementia, yet its recognition and understanding remain limited within the medical community. With an estimated prevalence of around 60,000 cases in the United States, FTD often eludes accurate diagnosis and is frequently mistaken for other conditions such as depression, Alzheimer’s disease, Parkinson’s disease, or psychiatric disorders. This course examines frontotemporal dementia in detail, exploring its presentation, types, causes, and diagnostics methods. It also explores current treatment options, potential complications, management strategies, and nursing considerations to improve the quality of life for individuals affected by frontotemporal dementia.
Course Objectives
Upon completion of this course, the learner will be able to:
- Review factors that increase the risk of developing dementia.
- Differentiate between the various types of frontotemporal dementia, including Behavioral variant frontotemporal dementia (bvFTD), Primary progressive aphasia (PPA) and Movement disorders.
- Understand the factors that increase the likelihood of developing frontotemporal dementia.
- Review treatment and management option for frontotemporal dementia.
- Understand nursing considerations when caring for patients with frontotemporal dementia, and resources available for family members.
Policy Statement
This activity has been planned and implemented in accordance with the policies of FastCEForLess.com.
Disclosures
Fast CE For Less, Inc and its authors have no disclosures. There is no commercial support.
To access Frontotemporal Dementia: A Quick Overview, purchase this course or a Full Access Pass.
If you already have an account, please sign in here.
To access Frontotemporal Dementia: A Quick Overview, purchase this course or a Full Access Pass.
If you already have an account, please sign in here.
| Alcohol-Related Dementia | A form of dementia caused by long-term, excessive consumption of alcohol, resulting in neurological damage and impaired cognitive function. |
| Alien Limb Phenomenon | Refers to involuntary motor activity of a limb in conjunction with the feeling of estrangement from that limb. |
| Alzheimer’s Disease | A type of dementia that affects memory, thinking, and behavior. |
| Amyotrophic Lateral Sclerosis (ALS) | A nervous system disease that affects nerve cells in the brain and spinal cord. |
| Apathy | Lack of interest, enthusiasm, or concern. |
| Behavioral Variant Frontotemporal Dementia (bvFTD) | A common form of frontotemporal dementia that affects behavior, language, and thinking skills, which eventually causes personality changes, apathy, and social decline. |
| Brain Atrophy | A condition in which the brain or regions of the brain decrease or shrink in size. |
| Broca’s Area | Region of the brain that contains neurons involved in speech function. |
| Chronic Traumatic Encephalopathy (CTE) | A neurodegenerative condition associated with repeated head injuries or concussions. |
| Declarative Memory | Also known as explicit memories, is a type of long-term memory that involves conscious recall of facts and events that one has personally experienced. |
| Dementia | A term for a range of conditions that affect the brain’s ability to think, remember, and function normally. |
| Disinhibition | Saying or doing something on a whim, without thinking in advance of what could be the unwanted or even dangerous result. |
| Dysgraphia | A learning disability that affects writing skills, such as handwriting, spelling, and word choice. |
| Dyslexia | A learning disability that affects either reading or writing. |
| Emotional Blunting | The inability to experience both positive and negative emotions fully. |
| Episodic Memory | A type of long-term memory that stores personal events with their context. |
| Frontal Gyrus | The lowest gyrus of the frontal lobe. |
| Frontal Lobe | The brain’s largest region, located behind the forehead, at the front of the brain. |
| Frontotemporal Dementia (FTD) (Pick’s Disease) | Several disorders that affect the frontal and temporal lobes of the brain that causes changes in personality and behavior. |
| Frontotemporal Lobar Degeneration (FTLD) | A pathological process that occurs in frontotemporal dementia. |
| Fused In Sarcoma (FUS) Protein | An RNA-binding protein with diverse roles in transcriptional activation and RNA splicing. |
| Hyperorality | The compulsive need to place both edible and inedible objects in one’s mouth. |
| Logopenic PPA (lvPPA) | A large build-up of proteins called amyloid and tau within brain cells, which are the same proteins that build up in Alzheimer’s disease. |
| Lou Gehrig’s Disease | A progressive neurological disorder which results in weakened muscles and deformity. |
| Magnetic Resonance Imaging (MRI) | A noninvasive imaging technique that uses magnetic field and radio waves to create detailed images of the organs and tissues in the body. |
| Memory Loss | A normal part of aging or a sign of a serious condition, such as Alzheimer’s disease or dementia. |
| Microtubule-Associated Protein Tau (MAPT) | Promotes assembly and interaction of microtubules with the cytoskeleton, impinging on axonal transport and synaptic plasticity. |
| Middle Cranial Fossa | Formed by the sphenoid bones, and the temporal bones. |
| Mutism | An absence of speech, with or without an ability to hear the speech of others. |
| Parietal Lobe | A part of the cerebral cortex that integrates sensory information, spatial awareness, and attention. |
| Parkinson’s Disease | A brain disorder that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination. |
| Positron Emission Tomography (PET) Scan | A powerful imaging technique that reveals the activity of cells in the body. |
| Primary Auditory Cortex | A part of the temporal lobe that processes sound information and language comprehension. |
| Primary Progressive Aphasia (PPA) | A rare syndrome that affects communication skills and is a type of frontotemporal dementia. |
| Progranulin (GRN) | A highly conserved secreted protein that is expressed in multiple cell types, both in the CNS and in peripheral tissues. |
| Progressive Nonfluent Aphasia (PNFA) | A disorder of language characterized by nonfluent, spontaneous speech with hesitancy, agrammatism, and phonemic errors, requiring significant effort in speech production. |
| Progressive Supranuclear Palsy (PSP) | A neurodegenerative condition that causes problems with balance, vision, speech, movement, and swallowing. |
| Recollection | The action or power of recalling to mind. |
| Repetitive Transcranial Magnetic Stimulation | A noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain for depression, OCD, migraines, and smoking cessation. |
| Selective Serotonin Reuptake Inhibitor (SSRI) | A type of antidepressant that increase levels of serotonin in the brain by blocking its reuptake. |
| Semantic Memory | A form of long-term memory that comprises a person’s knowledge about the world. |
| Semantic primary progressive aphasia (svPPA) | A type of frontotemporal dementia that involves difficulties with word and object recognition. |
| Stroke | Occurs when the supply of blood to the brain is reduced or blocked completely, which prevents brain tissue from getting oxygen and nutrients. |
| Tau Variant | An important protein for maintaining the shape and normal function of nerve cells. |
| Temporal Lobe | A part of the brain that helps one to use senses, process information, store and retrieve memories, and understand language. |
| Transactive DNA Binding Protein 43 (TDP-43) | A DNA and RNA binding protein involved in RNA processing and with structural resemblance to heterogeneous ribonucleoproteins (hnRNPs). |
| Transcranial Direct Current Stimulation | A popular brain stimulation method that is used to modulate cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviors. |
| Traumatic Brain Injury | A head injury that causes damage to the brain by external force or mechanism. It causes long term complications or death. |
Dementia is a pressing global health issue affecting millions of individuals worldwide. Currently, more than 55 million people live with dementia, with over 60% residing in low- and middle-income countries. Each year, an estimated 10 million new cases of dementia emerge, contributing to the escalating burden of the disease. In the United States alone, approximately 5 million men and women aged 65 and older are affected by dementia, a number projected to soar to nearly 14 million by 2060. Despite its incidence, dementia is not a normal aspect of aging. While aging increases the likelihood of developing dementia, many older adults live their lives without experiencing its debilitating effects. Dementia arises from a diverse array of diseases and injuries that affect the brain, causing cognitive decline and functional impairment. Frontotemporal Dementia (FTD) represents a distinct form of dementia, yet its recognition and understanding remain limited within the medical community. With an estimated prevalence of around 60,000 cases in the United States, FTD often eludes accurate diagnosis and is frequently mistaken for other conditions such as depression, Alzheimer’s disease, Parkinson’s disease, or psychiatric disorders. On average, it takes approximately 3.6 years to receive an accurate diagnosis of FTD, highlighting the challenges associated with identifying and managing this complex neurodegenerative condition.1,2
This course examines frontotemporal dementia (FTD) in detail, exploring its presentation, types, causes, and diagnostics methods. It also explores current treatment options, potential complications, management strategies, and nursing considerations to improve the quality of life for individuals affected by FTD.
Dementia is a complex syndrome characterized by the progressive deterioration of cognitive functions caused by damage to nerve cells and impairments in brain function. While aging may lead to cognitive decline, dementia represents a significant departure from typical age-related changes, affecting memory, thinking, behavior, and emotional control. It encompasses various types, including vascular dementia, Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia. Alzheimer’s disease is the most prevalent form, contributing to 60–70% of dementia cases globally. Vascular dementia is caused by diminished blood flow to the brain, often due to small vessel disease. Dementia with Lewy bodies is characterized by abnormal protein deposits in the brain, as seen in Parkinson’s disease, leading to fluctuations in cognitive abilities, visual hallucinations, and motor symptoms. Frontotemporal dementia affects the frontal and temporal lobes of the brain, leading to changes in behavior, personality, and language abilities.3,4
Dementia can also arise from various other factors, including strokes, infection, chronic alcohol use, repetitive brain injuries, and nutritional deficiencies. Strokes disrupt blood flow to parts of the brain, starving brain cells of vital oxygen and nutrients, leading to damage and cognitive impairment. Infections such as human immunodeficiency virus (HIV) cause systemic inflammation, which also damages brain cells, contributing to dementia. Chronic alcohol misuse may result in a condition known as alcohol-related dementia, characterized by cognitive deficits and memory impairment. Repetitive brain injuries, as seen in chronic traumatic encephalopathy (CTE), commonly found in athletes or individuals with a history of head trauma, can lead to progressive cognitive decline and behavioral changes. Nutritional deficiencies, particularly vitamin B12 and folate, can also impair cognitive function and contribute to the development of dementia. 3,4
Early signs and symptoms of dementia include forgetting recent events or information, misplacing or losing items regularly, getting lost in familiar places, feeling confused in familiar settings, losing track of time, facing challenges in problem-solving and decision-making, struggling to follow conversations or find appropriate words, difficulty in performing routine tasks, and misjudging distances or experiencing visual perception issues. Individuals with dementia often exhibit changes in mood and behavior, including feelings of anxiety, sadness, or frustration related to memory loss and cognitive decline, noticeable shifts in personality traits, engaging in inappropriate behaviors or actions, withdrawal from work, social activities, or interactions, and reduced interest or empathy towards others’ emotions. However, dementia manifests differently in each individual as it is influenced by various factors such as underlying causes, concurrent health conditions, and pre-existing cognitive functioning. Symptoms typically worsen over time, with some fluctuating or disappearing, while others become more pronounced in the later stages.3,4
Frontotemporal dementia (FTD), also known as frontotemporal lobar degeneration (FTLD) or Pick’s disease, is a type of dementia characterized by the degeneration of neurons in the brain’s frontal and temporal lobes. The frontal lobe, the largest lobe of the brain, resides in front of the cerebral hemispheres and plays a decisive role in various functions essential for our body’s overall functioning. One of its key roles is in prospective memory, which involves the ability to remember plans and intentions made for the future, whether they are simple daily tasks or lifelong goals. The frontal lobe also houses Broca’s area in the posterior inferior frontal gyrus, which plays a fundamental role in formulating and articulating words and sentences, verbal communication, and language comprehension. The frontal lobe is also closely intertwined with personality traits and behavioral tendencies. It regulates aspects of personality expression, emotional responses, and social behavior, with damage or dysfunction in this area potentially leading to alterations in personality, such as impulsivity, apathy, or disinhibition. The frontal lobe has been shown to process decision-making, enabling individuals to evaluate options, weigh consequences, and make informed choices based on past experiences and future goals.
Lastly, the frontal lobe governs movement control, serving as a command center for initiating and regulating movements throughout the body. Motor areas within the frontal lobe facilitate the planning and execution of precise movements, ensuring smooth motor coordination and control.5-8
The temporal lobe is the second most substantial portion of the brain, occupying the middle cranial fossa. The temporal lobe lies posterior to the frontal lobe and inferior to the parietal lobe, encompassing several critical functions essential for perception, memory, and sensory processing. One of its primary roles is housing the primary auditory cortex, which is responsible for translating and processing all sounds and tones the individual perceives. It is also involved in visual perception and facial recognition.
Recent research shows the temporal lobe processes several forms of memory, including: 5-8
- Semantic memory, which involves remembering common knowledge, such as the location of objects like the bathroom.
- Declarative memory, a type of long-term memory responsible for remembering concepts, ideas, and events learned throughout one’s life.
- Recollection, the ability to remember an object or event and its varying details, including time and place.
- Familiarity, recognizing an object or person without recalling specific details about the encounter.
- Episodic memory, which allows individuals to recall specific events and their associated details, consciously remembering past events and experiences.
Although the age of FTD onset is from 21 to 90, an estimated 60% of individuals diagnosed are middle-aged, between 45 to 64 years old. However, predicting the course of FTD and its impact on an individual’s lifespan can be challenging due to its variability among patients. What is known is FTD is progressive in nature, meaning that symptoms will worsen over time as the disease advances. Initially, individuals may exhibit only one symptom during the disease’s early stages, with additional symptoms emerging as more parts of the brain become affected by the degenerative process. Some individuals may live more than 10 years after receiving a diagnosis, while others may experience a more rapid decline and survive for less than two years post-diagnosis. Average life expectancy typically falls between 7 to 13 years after symptoms start.9,10
There are several types of Frontotemporal Dementia (FTD) currently defined for diagnostic purposes: 5,9
- Behavioral variant frontotemporal dementia (bvFTD)
- Primary progressive aphasia (PPA)
- Movement disorders
Behavioral Variant Frontotemporal Dementia
Behavioral variant frontotemporal dementia (bvFTD) is the most prevalent form of FTD. It accounts for approximately half of all cases of the disease. Unlike Alzheimer’s disease, where memory impairment is a prominent feature, bvFTD primarily manifests through changes in personality, behavior, and judgment, including symptoms such as disinhibition, apathy, emotional blunting, compulsive or ritualistic behaviors, changes in eating habits or diet, hyperorality, and deficits in executive function. Disinhibition involves a lack or loss of restraint based on social norms, leading to inappropriate behavior and impulsivity. Examples include making rude or offensive comments, disregarding personal space, engaging in shoplifting or reckless spending, exhibiting inappropriate sexual behavior, and experiencing aggressive outbursts. Apathy refers to the indifference or lack of interest individuals with bvFTD may display in activities that were previously meaningful to them. For example, a loss of interest in hobbies, work, and personal relationships, neglect of personal hygiene, and a general loss of initiative. Emotional blunting manifests as a loss of warmth, empathy, or concern for others, leading to indifference toward important events and failure to recognize the emotional states of loved ones. Compulsive or ritualistic behaviors include repetitive behaviors or routines, such as repeating words or phrases, performing hand movements, re-reading the same book repeatedly, hoarding items, or adhering strictly to specific schedules. Changes in eating habits or diet typically present as excessive, compulsive, or inappropriate eating and drinking behaviors, including binge eating, carbohydrate craving, or selective eating of certain foods. Increased or first-time use of tobacco products may also occur. Hyperorality involves excessively consuming water or alcohol or attempting to ingest inedible objects. Deficits in executive function include poor decision-making, judgment, problem-solving, and organizational skills. This, in turn, leads to difficulties in planning daily activities, making financial decisions, and increased mistakes at work or in daily tasks.
Along with these symptoms, individuals with bvTFD typically remain in a state of agitation and emotional instability. They have frequent mood changes and lack awareness of the changes in their behavior and its impact on others. They are prone to blame others for the consequences of their socially unacceptable behavior and may experience anger at limitations on their activities.5,10
Primary Progressive Aphasia
Primary progressive aphasia (PPA) encompasses a spectrum of language-related impairments that affect the ability to speak, read, write, and understand spoken language. It is characterized by a gradual decline in language abilities, which may include difficulty in using or comprehending words (aphasia) and difficulty articulating speech properly, leading to slurred speech or mutism. As it progresses, many individuals with PPA eventually develop symptoms of dementia. However, memory issues, reasoning deficits, and judgment impairments may not be immediately apparent and typically emerge slowly over time. In some cases, individuals with primary progressive aphasia may experience significant behavioral alterations akin to those observed in bvFTD as the disease advances. Clinically, primary progressive aphasia is categorized into three main types:
- Nonfluent/agrammatic primary progressive aphasia
- Semantic primary progressive aphasia
- Logopenic primary progressive aphasia
The type of PPA a person experiences is determined by the nature of the language difficulties they exhibit, and the specific regions of the brain affected by the degenerative process.5,12
Nonfluent/agrammatic PPA (nfvPPA), also known as progressive nonfluent aphasia (PNFA), refers to progressing challenges in verbal expression while retaining the ability to comprehend the meanings of individual words. The speech difficulty is caused by the degeneration of brain regions responsible for controlling the lip and tongue muscles utilized in speech production. Despite the muscles themselves remaining unaffected, individuals with nfvPPA experience distorted or inaccurate speech sounds that are slow and laborious, with groping movements of the face and mouth in attempts to articulate sounds correctly. The onset of effortful speech often marks the initial symptom, with multisyllabic words proving particularly challenging to pronounce accurately. However, speech difficulties alone do not suffice for diagnosing PPA. The distinguishing feature lies in the impairment of grammar. Individuals with nfvPPA frequently make errors in speech, such as omitting words, rearranging sentence structures, and misusing word endings, verb tenses, and pronouns.5,13
Consequently, speech becomes confined to short, simplistic phrases, hindering comprehension for listeners due to omissions and linguistic errors. For instance, affected individuals may substitute “seed” for “saw”, resulting in fragmented utterances like “Today…go dinner…ah…brother” to convey “Today I am going to dinner with my brother.” Nonfluent/agrammatic PPA also includes impaired ability to comprehend lengthy or intricate sentences, particularly those with grammatical complexity. While single-word comprehension remains intact, individuals with nonfluent/agrammatic PPA may struggle with processing excessive verbal information, such as following conversations in group settings or comprehending television programs. As the disease progresses, nfvPPA may lead to mutism, the inability to speak altogether. In later stages, swallowing may become difficult, and motor symptoms resembling Parkinson’s disease may emerge. These include slow, stiff movements, balance issues, frequent falls, difficulty using limbs, and restricted up-and-down eye movements.5,13
Semantic PPA (svPPA) is characterized by a gradual decline in recognizing familiar faces and objects and understanding single words, particularly those that are less familiar or infrequently used. This can cause confusion and errors in understanding verbal instructions or descriptions. While other language skills, such as speech production and sentence repetition, remain intact, affected individuals may exhibit vague and difficult-to-understand speech patterns due to word omissions or substitutions. For example, refer to a “car” as a “truck.” Combined, these issues can lead to significant challenges in communication and comprehension. As svPPA progresses, individuals often have difficulty remembering the identity and function of familiar objects and present with surface dyslexia and dysgraphia, difficulty reading and writing words that do not adhere to pronunciation or spelling rules such as “broad” as “brode” or “no” instead of “know.”5,14
Logopenic PPA (lvPPA) presents distinctive language difficulties characterized by the struggle to find the right words during conversations while maintaining comprehension of words and sentences. Unlike svPPA, individuals with lvPPA do not encounter difficulties with grammar and retain the ability to recall word meanings. It also differs from agrammatic PPA such that speech fluency remains intact during casual conversation. However, speech is prone to becoming hesitant when more specific or unfamiliar words are required. Importantly, speech in lvPPA typically remains free from effort and distortion. Individuals with lvPPA often exhibit a narrow attention span for words, leading to challenges in word retrieval, difficulty in repeating longer phrases and sentences, phonological speech errors such as omissions and substitutions, and repetition of phrases and sentences. They often rely on extended descriptions or circumlocution to compensate for forgotten words. As the disease progresses, affected individuals may encounter increasing difficulty in comprehending complex sentences, further impeding their ability to engage in fluent communication. In advanced stages, lvPPA may lead to swallowing difficulties.5,15
Movement Disorders
Movement disorders associated with FTD include two rare neurological conditions that affect the regions of the brain responsible for controlling movement:
- Corticobasal syndrome
- Progressive supranuclear palsy
Corticobasal syndrome is often linked with corticobasal degeneration, characterized by the gradual atrophy and loss of nerve cells in specific brain regions. Symptoms typically emerge around 60 and may include limb apraxia, which is the inability to move or conduct a desired motion, although muscle strength is present. This leads to difficulty completing purposeful activities, such as using kitchen utensils or opening a door. It also leads to frequent falls or tripping. Other manifestations of corticobasal syndrome can include muscle rigidity, difficulty swallowing, and asymmetric motor symptoms that eventually affect both sides of the body. In some cases, individuals may initially experience language difficulties before the onset of movement-related symptoms. Cognitive symptoms include the sensation a limb is not part of the body (alien limb phenomenon), inability to do simple mathematical calculations, and difficulty orienting in space.5,16
Progressive supranuclear palsy (PSP) presents with problems related to balance and walking, often leading to slow movements, unexplained falls, loss of facial expression, and stiffness in the neck and upper body, as seen in Parkinson’s disease. A defining characteristic of PSP is impaired eye movements, particularly downward gaze, resulting in a fixed stare. Behavioral, memory, problem-solving, and judgment issues may also arise with disease progression. Other symptoms include slurred or slowed speech, resulting from difficulties in moving the muscles that control the lips, tongue, and jaw, and difficulty swallowing. Behavioral and emotional symptoms present alongside motor manifestations include the inability to regulate behavior, depression, apathy, and emotional instability.5,17
Additional movement-related types of frontotemporal dementia, such as FTD with parkinsonism and FTD with amyotrophic lateral sclerosis (FTD-ALS). Frontotemporal dementia with parkinsonism, often caused by a genetic 0 , manifests with movement difficulties akin to Parkinson’s disease, alongside the behavioral and language changes seen in bvFTD. FTD-ALS see the combined effect of behavioral and language alterations characteristic of FTD with the progressive muscle weakness observed in ALS, also known as Lou Gehrig’s disease. Individuals with FTD-ALS may experience fine muscle jerks and weakness, with symptoms of either disease potentially appearing first, and then evolving over time. While certain genetic mutations have been identified in some FTD-ALS cases, most instances are not hereditary.5,18
Frontotemporal dementia can arise from various underlying causes, contributing to the diverse manifestations of the condition. Primary causes of FTD have been linked to genetic factors, protein abnormalities, neuronal degeneration, and environmental factors. Approximately 10% of all cases of FTD have been found to have a genetic link. Certain types of FTD, such as bvFTD, have been shown to have a hereditary link with specific genetic mutations playing a significant role in its development. Mutations in genes such as C9orf72, microtubule-associated protein tau (MAPT), and progranulin (GRN) located on chromosome 17q21.32 have been implicated in familial forms of FTD. Protein abnormalities have been seen in postmortem studies, revealing abnormal protein accumulation within the brain. Notably, abnormal tau protein or transactive DNA binding protein 43 (TDP-43) within nerve cells in the frontotemporal lobes is present. The proteins contribute to neuronal damage and dysfunction, leading to cell death and atrophy in brain regions. In a minority of cases, accumulation of the fused in sarcoma (FUS) protein may occur instead of tau or TDP-43, as observed in some instances of frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). The degeneration and loss of neurons in the brain’s frontal and temporal lobes can also contribute to the development of FTD. This neuronal degeneration disrupts the normal functioning of these brain regions, leading to cognitive, behavioral, and language impairments characteristic of FTD. Recent studies have shown that environmental factors may also contribute to its development. For example, exposure to certain toxins such as heavy metals, pesticides, or industrial chemicals, head trauma, and other environmental stressors such as chronic psychological stress or viral infections may damage neurons or trigger pathways that lead to FTD. However, the specific mechanisms involved are still under study. 5,19,20
Several risk factors have been identified that may increase the likelihood of developing FTD, including genetic predisposition, age, gender, history of head trauma, environmental exposure, and lifestyle choices. Family history plays a significant role in FTD risk, with certain genetic mutations strongly associated with the disease’s familial forms. Mutations in genes such as C9orf72, MAPT, and GRN have been implicated in inherited cases of FTD. While FTD can affect individuals of varying ages, it most commonly manifests in mid-to-late adulthood, typically between the ages of 40 and 65, making advanced age a considerable risk factor. Some studies suggest that FTD may affect people differently, with certain subtypes of the condition being more prevalent in one gender over the other. However, there is no definitive clinical evidence, and further research is needed to fully understand the relationship between gender and FTD risk. Traumatic brain injury, particularly repeated or severe head trauma, has been identified as a likely risk factor for FTD. However, the exact mechanisms of FTD are not fully understood but may involve inflammation and related neuronal damage. Extended exposure to certain environmental toxins, such as heavy metals, pesticides, and industrial chemicals, may increase the risk, especially if proper precautions are not taken when managing such substances. Studies have shown certain lifestyle factors, such as smoking, excessive alcohol consumption, obesity, and a sedentary lifestyle, may also contribute to an increased risk of FTD. These factors can negatively affect overall brain health and may exacerbate underlying genetic FTD predispositions.21,22
Diagnosing FTD is inherently complex, especially during the early stages of the disease. The challenge primarily stems from the diverse and often subtle array of symptoms exhibited by individuals with FTD, which can overlap with those of other neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease. The variability in symptom presentation also adds to the difficulty of reaching a definitive diagnosis. In the initial phases, FTD symptoms, including changes in behavior, language difficulties, and alterations in personality may appear nonspecific. These manifestations are often mistakenly attributed to mood disorders like depression or anxiety, delaying accurate diagnosis and appropriate intervention. Furthermore, the progressive nature of FTD means that symptoms evolve over time, making it challenging to differentiate from other conditions solely based on presentation. Differentiating between the various subtypes of FTD requires a thorough evaluation of clinical symptoms. Evaluations may involve several diagnostic methods, such as comprehensive personal and family history, neuroimaging techniques, and extensive neuropsychological assessment.23,24
A clinical diagnosis of possible or probable FTD relies heavily on a comprehensive evaluation of the patient’s signs and symptoms by a skilled healthcare professional and multidisciplinary team. The evaluation should consider behavioral changes, social conduct, and cognitive functions, such as executive and language functioning. Family members and caregivers often provide crucial insights into the individual’s behavior and functional abilities, aiding in the diagnostic assessment. A psychiatric evaluation is also done to determine if depression, stress, anxiety, or another mental health concern is causing or contributing to the symptoms. While brain imaging, including structural magnetic resonance imaging (MRI) or functional positron emission tomography (PET) scans, can provide supportive evidence for FTD diagnosis by revealing specific patterns of brain atrophy or dysfunction in the frontal and temporal lobes, these imaging findings are not definitive. Currently, no single biomarker exists to conclusively diagnose FTD during life. As a result, definitive confirmation of FTD requires a neuropathological exam of brain tissue obtained through autopsy 23,24
Similarly, there is no definitive test for primary progressive aphasia (PPA). Its clinical diagnosis relies heavily on the presence of characteristic linguistic features, which are evaluated through detailed language assessments and cognitive testing. Speech and language therapists often play a crucial role in conducting these evaluations and observing the patient’s language abilities in various contexts. Neuropsychological assessments, including standardized language tests and comprehensive cognitive evaluations, help clinicians assess the extent and nature of language impairments in PPA. Additionally, neuroimaging techniques such as MRI scans may provide supportive evidence by revealing patterns of structural changes and focal cortical atrophy in the relevant regions of the temporal lobes, which are typically associated with PPA. For diagnosing specific subtypes of PPA, further clinical evaluation is necessary that considers a combination of specific symptoms indicative of the condition.23,24
Currently, there is no cure for any type of FTD, and in most cases, particularly for bvFTD, treatment options are limited, and progression cannot be slowed. Therefore, interventions focus primarily on managing symptoms and improving the quality of life for patients and their caregivers. Non-pharmacological approaches are accepted as the safest avenue for managing symptoms in bvFTD. Creating a structured and supportive environment can help minimize behavioral disturbances and improve patient safety. Strategies may include maintaining a consistent daily routine, providing clear and simple instructions, reducing environmental stimuli, and ensuring physical safety. While there are no specific medications approved for treating bvFTD, some drugs may be prescribed off-label to target specific symptoms. Selective serotonin reuptake inhibitors (SSRIs) like citalopram or sertraline may be used to alleviate symptoms of anxiety, depression, or irritability. Trazodone, an antidepressant with sedative properties, can help manage agitation and sleep disturbances in some cases. Atypical antipsychotic medications such as olanzapine, risperidone, and quetiapine are occasionally prescribed to address severe agitation, aggression, or psychosis in bvFTD. However, their use is limited due to the risk of adverse effects, including sedation, metabolic disturbances, and increased mortality, particularly in elderly patients.25,26
Similar interventions are also utilized for PPA. Therapeutic interventions such as transcranial direct current stimulation, repetitive transcranial magnetic stimulation, and speech-language therapy have demonstrated promising effects in some cases. However, further research is needed to elucidate the optimal dosage and timing of these treatments and their long-term impact on individuals with PPA. As individuals with PPA eventually develop behavioral, social, and motor complications commonly observed in bvFTD, treatment is adjusted accordingly to manage additional symptoms and keep the patient comfortable. As FTD progresses and cognitive and behavioral symptoms worsen, individuals may require increasing levels of support and supervision. Given the complexity of FTD and the lack of effective treatments, participation in clinical trials investigating potential therapies is encouraged. Research efforts aimed at understanding the underlying FTD mechanisms and developing targeted interventions continue to expand, offering hope for future breakthroughs in treatment. 25,26
For individuals with movement disorder-type FTD, various interventions can help alleviate FTD symptoms and improve quality of life. Physical therapy that incorporates stretching exercises and low-impact activities can help alleviate muscle symptoms and maintain mobility. Assistive devices like ramps, braces, walkers, and wheelchairs aid in conserving energy and promoting mobility. Speech therapy has also been shown to be beneficial for patients with movement disorder-type FTD in developing strategies for clearer speech. As the condition progresses, alternative communication methods, such as speech synthesizers, may become necessary to facilitate effective communication. In cases where the disorder presents with features of ALS, patients gradually lose the ability to perform basic motor functions independently. They may become unable to stand, walk, or perform activities of daily living without assistance. Difficulty swallowing and chewing can lead to nutritional challenges and an increased risk of choking. Eventually, patients may lose the ability to breathe independently, necessitating ventilator support for survival. 25,26
Frontotemporal dementia often leads to a spectrum of complications that significantly affect the individual’s daily life and overall health. Most notable is the increased risk of accidents and injuries. Due to behavioral changes associated with FTD, such as impulsivity, disinhibition, and poor judgment, individuals may engage in risky behaviors without considering the consequences. These behaviors can lead to falls, burns, traffic accidents, or other injuries, posing significant challenges for caregivers and healthcare providers in ensuring the safety and well-being of the affected individual. Individuals with FTD also may experience coexisting mental health conditions, including depression and anxiety. These conditions can exacerbate FTD symptoms and further impair cognitive and emotional functioning. Depression may manifest as persistent feelings of sadness, hopelessness, and apathy, contributing to social withdrawal and decreased interest in activities.
Anxiety, on the other hand, can lead to increased agitation, restlessness, and difficulty coping with everyday stressors, further complicating the management of FTD symptoms. Individuals with FTD may face challenges in maintaining social relationships and engaging in meaningful activities due to cognitive and behavioral changes. Social withdrawal, inappropriate behaviors, and communication difficulties can strain interpersonal relationships and lead to feelings of isolation and loneliness for both the affected individual and their caregivers. This social isolation can further exacerbate depressive symptoms and negatively impact the individual’s overall quality of life.5,20,23,25
Given the complex nature of FTD and its potential complications, a comprehensive approach to care is essential. This approach involves multidisciplinary collaboration among healthcare professionals to address the diverse needs of individuals with FTD and provide tailored support and interventions. Management starts with education and support for both patients and caregivers. Understanding the nature of FTD, its progression, and its challenges can help individuals and their families better cope with the changes and plan for the future. Support groups, educational resources, and counseling services can offer valuable information and emotional support to individuals and families navigating the complexities of FTD. Behavioral interventions play a key role in managing FTD-related symptoms, such as agitation, impulsivity, and disinhibition. Establishing routines, providing a structured environment, and minimizing environmental stressors can help reduce behavioral disturbances and improve predictability for individuals with FTD. 5,20,23,25
Additionally, strategies such as distraction, redirection, and reinforcement of positive behaviors can help mitigate challenging behaviors and enhance overall functioning. Pharmacological interventions may be considered in some cases to target specific symptoms of FTD, such as agitation, aggression, or mood disturbances. While medications can help alleviate symptoms to some extent, they should be used judiciously and under the guidance of a healthcare professional, as they may pose risks of adverse effects and interactions, particularly in older adults with FTD. Optimizing the physical health and well-being of individuals with FTD is essential. Regular physical activity, a nutritious diet, adequate hydration, and proper medical management of coexisting conditions can help support overall health and potentially slow disease progression. As FTD progresses, individuals may require increasing levels of assistance with daily living and daily activities. Caregivers provide practical assistance, emotional support, and supervision as needed to ensure both the safety and well-being of individuals with FTD. Accessing community resources, respite care services, and long-term care options can help alleviate caregiver burden and ensure continuity of care for individuals with FTD. 5,20,23,25
For caregivers and family members of individuals diagnosed with FTD, navigating the challenges of caregiving requires patience and a deep understanding of the condition’s progressive nature. To provide optimal care, family and caregivers need to fully understand the disease’s symptoms, stages, and progression. This allows them to anticipate changes, manage expectations, and provide appropriate support throughout the caregiving journey. Accessing reputable resources, attending support groups, and seeking guidance from healthcare professionals can offer valuable insights and practical strategies for effective caregiving. Maintaining open communication within the healthcare team is also essential for fostering collaboration, sharing responsibilities, and addressing emerging challenges proactively. Regular meetings or discussions provide opportunities to express concerns, explore potential solutions, and ensure that family members manage caregiving tasks effectively. Creating a safe environment tailored to the individual’s evolving needs is also crucial for promoting their well-being and preserving their sense of dignity and autonomy.
Reducing hazards in the living space, implementing memory aids and reminders, and establishing consistent routines can enhance predictability and reduce anxiety for individuals with FTD. Self-care is a vital aspect of effective caregiving. Caregivers must prioritize their physical, emotional, and psychological well-being to prevent burnout and maintain their capacity to provide high-quality care. Engaging in regular exercise and nurturing social connections outside of caregiving responsibilities are essential components of self-care. Seeking support from external resources and professional services can offer valuable assistance and relief for caregivers facing complex caregiving demands.
Utilizing respite care services, accessing home healthcare assistance, and enlisting the support of community organizations or dementia care specialists can alleviate caregiving burdens. It can also enhance the overall quality of care provided to individuals with FTD. It is equally important for family members and caregivers to acknowledge and process the emotional impact of caregiving. Coping with feelings of grief, guilt, frustration, and isolation is a natural part of the caregiving experience. Engaging in self-reflection, practicing mindfulness techniques, and seeking emotional support from peers, support groups, or mental health professionals can facilitate emotional resilience and promote caregiver well-being amidst the challenges of caring for a loved one with FTD.27-29
Several key considerations are vital to ensuring comprehensive and effective care delivery in nursing care for individuals with FTD. Regular and thorough assessments of behavioral and cognitive changes are essential for early detection of FTD progression and the development of appropriate care interventions. Nurses play a crucial role in conducting comprehensive assessments, including observing mood, behavior, language skills, and cognitive function changes. Continuous monitoring allows nurses to identify emerging symptoms, evaluate treatment responses, and adjust care plans to optimize patient outcomes.
To enhance communication with a patient with FTD, nurses must tailor their communication strategies to overcome the progressive challenges in language, comprehension, and social interactions a patient with FTD may face, including:
- Using simple language that is clear and concise, and avoid using complex sentences, jargon, or abstract concepts that may confuse or overwhelm the individual.
- Speak slowly by maintaining a moderate pace of speech and articulate words clearly.
- Allow sufficient time for the individual to process information and respond without feeling rushed or pressured. Use gestures, visual aids, and facial expressions to support verbal communication. (Visual cues can help reinforce meaning and facilitate comprehension for individuals with FTD who may have difficulty processing spoken language alone).
- Repeat key information or instructions as needed and provide reinforcement through positive feedback and encouragement. (Repetition can help reinforce learning and memory retention in individuals with FTD. Present questions in a straightforward manner that allows for simple yes or no responses). 5,20,23,25
- Avoid open-ended questions or vague inquiries that may lead to confusion or frustration.
- Listen attentively to the individual’s responses and validate their feelings and experiences.
- Practice patience and flexibility when communicating with individuals with FTD, acknowledging their challenges in expressing themselves or understanding information. Allow extra time and offer reassurance during moments of frustration or confusion.
- Minimize environmental distractions such as loud noises, cluttered surroundings, or competing stimuli that may disrupt communication and focus.
- Create a calm environment conducive to meaningful interaction.
- Demonstrate empathy, patience, and understanding during interactions to foster a supportive and respectful communication environment.
- Maintain appropriate eye contact and body language to convey warmth, respect, and trust during communication.
As each individual with FTD presents unique symptoms, challenges, and care needs, personalized interventions are necessary. Nurses must collaborate with patients, family members, and interdisciplinary healthcare teams. Individualized care plans can be tailored to the patient’s preferences, abilities, and goals. 5,20,23,25
Frontotemporal dementia (FTD) is a multifaceted neurodegenerative condition characterized by the progressive degeneration of neurons in the brain’s frontal and temporal lobes. Accurate diagnosis of FTD requires a comprehensive evaluation of clinical symptoms, cognitive function, behavioral changes, and neuroimaging findings. Although no cure exists, various management strategies can alleviate symptoms, improve quality of life, and support individuals and their caregivers throughout the disease progression. Comprehensive care is central and involves a multidisciplinary approach, incorporating physical, emotional, and social support tailored to the individual’s evolving needs.
Caregivers and family members play a pivotal role in providing practical assistance and emotional support, as well as advocating for the needs of individuals with FTD. Nursing care for individuals with FTD requires specialized knowledge, effective communication strategies, and personalized interventions to promote safety, well-being, and dignity.
Moving forward, continued research efforts are essential to advance our understanding of FTD’s underlying mechanisms, identify novel therapeutic targets, and develop more effective treatments. Enhanced public awareness, education, and support services are vital to address the growing burden of FTD and improve outcomes for individuals affected by this challenging condition. By fostering collaboration among healthcare professionals, researchers, policymakers, and community stakeholders, we can strive towards comprehensive care, improved quality of life, and, ultimately, better outcomes for individuals living with FTD.
- Dementia. (n.d.). Www.who.int. Retrieved March 8, 2024, from https://www.who.int/news-room/fact-sheets/detail/dementia/?gad_source=1&gclid=CjwKCAiA6KWvBhAREiwAFPZM7iLtXI9IHou9SYl_huFAok9Pzn2VoYoAryiEo4r9egvi9hOxaMLEkhoC1dkQAvD_BwE
- CDC. (2019, April 5). What Is dementia? Centers for Disease Control and Prevention. https://www.cdc.gov/aging/dementia/index.html
- Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019). Diagnosis and Management of Dementia: A Review. JAMA, 322(16), 1589. https://doi.org/10.1001/jama.2019.4782
- Duong, S., Patel, T., & Chang, F. (2017). Dementia: What pharmacists need to know. Canadian Pharmacists Journal : CPJ, 150(2), 118-129. https://doi.org/10.1177/1715163517690745
- Young, J. J., Lavakumar, M., Tampi, D., Balachandran, S., & Tampi, R. R. (2017). Frontotemporal dementia: Latest evidence and clinical implications. Therapeutic Advances in Psychopharmacology, 8(1), 33-48. https://doi.org/10.1177/2045125317739818
- American Association of Neurological Surgeons. (2019). A Neurosurgeon’s Overview of the Brain’s Anatomy. Aans.org. https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Anatomy-of-the-Brain
- Cerebrum – an overview | ScienceDirect Topics. (2012). Sciencedirect.com. https://www.sciencedirect.com/topics/neuroscience/cerebrum
- Herbet, G., & Duffau, H. (2020). Revisiting the Functional Anatomy of the Human Brain: Toward a Meta-Networking Theory of Cerebral Functions. Physiological Reviews, 100(3), 1181–1228. https://doi.org/10.1152/physrev.00033.2019
- Frontotemporal Dementia and Other Frontotemporal Disorders | National Institute of Neurological Disorders and Stroke. (n.d.). Www.ninds.nih.gov. https://www.ninds.nih.gov/health-information/disorders/frontotemporal-dementia-and-other-frontotemporal-disorders
- What is FTD? (n.d.). AFTD. https://www.theaftd.org/what-is-ftd/disease-overview/
- What is BvFTD? (Behavioral Variant FTD), Pick’s Disease. (n.d.). AFTD. https://www.theaftd.org/what-is-ftd/behavioral-variant-ftd-bvftd/
- Primary Progressive Aphasia (PPA) | AFTD. (2019, February 5). https://www.theaftd.org/what-is-ftd/ftd-disorders/primary-progressive-aphasia/
- Nonfluent/Agrammatic PPA (Primary Progressive Aphasia) | AFTD. (2018, March 2). https://www.theaftd.org/what-is-ftd/primary-progressive-aphasia/nonfluent-agrammatic-ppa-nfvppa/
- Semantic Variant PPA (Primary Progressive Aphasia). (n.d.). AFTD. https://www.theaftd.org/what-is-ftd/primary-progressive-aphasia/semantic-variant-ppa-svppa/
- Logopenic Variant PPA (Primary Progressive Aphasia) | AFTD. (2018, March 2). https://theaftd.org/what-is-ftd/primary-progressive-aphasia/logopenic-variant-ppa/
- Corticobasal Syndrome – Frontotemporal Degeneration | AFTD. (2018, March 2). https://www.theaftd.org/what-is-ftd/corticobasal-syndrome/
- Progressive Supranuclear Palsy | AFTD. (2018, March 2). AFTD. https://www.theaftd.org/what-is-ftd/progressive-supranuclear-palsy/
- ALS and Frontotemporal Degeneration | AFTD. (2011). AFTD. https://www.theaftd.org/what-is-ftd/ftd-and-als-ftd-als/
- Olszewska, D. A., Lonergan, R., Fallon, E. M., & Lynch, T. (2016). Genetics of Frontotemporal Dementia. Current Neurology and Neuroscience Reports, 16(12). https://doi.org/10.1007/s11910-016-0707-9
- Currens, L., Harrison, N., Schmidt, M., Amjad, H., Mu, W., Scholz, S. W., Bang, J., & Pantelyat, A. (2023). A case of familial frontotemporal dementia caused by a progranulin gene mutation. Clinical Parkinsonism & Related Disorders, 9. https://doi.org/10.1016/j.prdoa.2023.100213
- Eid, H. R., Rosness, T. A., Bosnes, O., Salvesen, Ø., Knutli, M., & Stordal, E. (2019). Smoking and Obesity as Risk Factors in Frontotemporal Dementia and Alzheimer’s Disease: The HUNT Study. Dementia and Geriatric Cognitive Disorders EXTRA, 9(1), 1-10. https://doi.org/10.1159/000495607
- Soppela, H., Katisko, K., Gadola, Y., Krüger, J., Hartikainen, P., Alberici, A., Benussi, A., Koivisto, A., Haapasalo, A., Remes, A. M., Borroni, B., & Solje, E. (2022). Modifiable potential risk factors in familial and sporadic frontotemporal dementia. Annals of Clinical and Translational Neurology, 9(8), 1195-1205. https://doi.org/10.1002/acn3.51619
- Bott, N. T., Radke, A., Stephens, M. L., & Kramer, J. H. (2014). Frontotemporal dementia: Diagnosis, deficits, and management. Neurodegenerative Disease Management, 4(6), 439. https://doi.org/10.2217/nmt.14.34
- Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022). Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. The Lancet Neurology, 21(3), 258–272. https://doi.org/10.1016/s1474-4422(21)00341-0
- Tsai, R. M., & Boxer, A. L. (2014). Treatment of Frontotemporal Dementia. Current Treatment Options in Neurology, 16(11), 319. https://doi.org/10.1007/s11940-014-0319-0
- Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L. (2022). Advances in Treatment of Frontotemporal Dementia. The Journal of Neuropsychiatry and Clinical Neurosciences, 34(4), 316–327. https://doi.org/10.1176/appi.neuropsych.21060166
- Caceres, B. A., Frank, M. O., Jun, J., Martelly, M. T., Sadarangani, T., & De Sales, P. C. (2016). Family caregivers of patients with frontotemporal dementia: An integrative review. International Journal of Nursing Studies, 55, 71-84. https://doi.org/10.1016/j.ijnurstu.2015.10.016
- Sagbakken, M., Nåden, D., Ulstein, I., Kvaal, K., Langhammer, B., & Rognstad, M.-K. (2017). Dignity in people with frontotemporal dementia and similar disorders — a qualitative study of the perspective of family caregivers. BMC Health Services Research, 17(1). https://doi.org/10.1186/s12913-017-2378-x
- Rasmussen, H., Hellzen, O., Stordal, E., & Enmarker, I. (2019). Family caregivers experiences of the pre-diagnostic stage in frontotemporal dementia. Geriatric Nursing, 40(3), 246-251. https://doi.org/10.1016/j.gerinurse.2018.10.006
To access Frontotemporal Dementia: A Quick Overview, purchase this course or a Full Access Pass.
If you already have an account, please sign in here.
To access Frontotemporal Dementia: A Quick Overview, purchase this course or a Full Access Pass.
If you already have an account, please sign in here.
